跳到正文
原文
Medical Xpress·· 2026-10-15AI 评分42

Nature Communications:IIT 团队开发可逆基因开关,或提升 CAR-T 免疫治疗精准控制

Reversible genetic switches could give cancer immunotherapy more precise control

AI 导读

意大利 IIT 团队在 Nature Communications 报道一种可逆基因开关,可让 CAR-T 细胞在识别肿瘤抗原时开启、肿瘤消失后关闭。研究将开关连接荧光蛋白,追踪其开启、关闭和再开启,显示该合成启动子工具可编程控制基因表达。目前尚未连接治疗性分子,团队称技术已准备与临床免疫学家合作测试。

正文
IIT develops a new strategy against cancer: immunotherapies with a switch
When CAR-T cells recognize tumor antigens, a genetic switch activates an added gene. Researchers linked this switch to a gene producing a fluorescent protein, allowing them to track it turning on, off and on again. Credit: IIT-Istituto Italiano di Tecnologia

A genetic switch that activates immune cells as they fight tumors: this is the new strategy developed by an international research team coordinated by Velia Siciliano at the Istituto Italiano di Tecnologia (IIT—Italian Institute of Technology) in Naples and described in the journal Nature Communications. The study marks another step toward engineering precise and more effective synthetic immunotherapies against solid tumors, such as melanoma and breast cancer.

The international collaboration brings together Siciliano's group at IIT in Naples, the University of Edinburgh and the Leibniz Institute for Immunotherapy (LIT) in Regensburg, combining complementary expertise in synthetic biology, immunology and artificial intelligence.

T-cell-based immunotherapies are among the most promising strategies against cancer, but researchers are working to precisely control their activity and long-term effectiveness once they are circulating in the body. Cancer cells can be highly resistant, weakening the action of T cells.

Therapeutic genes activated on demand

Siciliano's research aims to enhance genetically modified T cells, known as CAR-T cells, through synthetic biology circuits that give immune cells specific properties. In this latest study, Siciliano and her team have developed a new technology that introduces a switch into CAR-T cells, controlling the activation of therapeutic genes only when the cells receive specific biological signals from cancer cells.

"Synthetic biology allows us to modify immune cells to make them more effective. In this study, we added a kind of switch that turns T cells on and off like light bulbs when they come into contact with cancer cells, activating programs that support their action. When the tumor is no longer present, these switches turn off, preventing side effects," explains Siciliano, head of the Synthetic and Systems Biology for Biomedicine laboratory at IIT's center in Naples.

Testing a reversible genetic switch

The switch consists of short stretches of DNA, known as synthetic promoters, that control the activation of an added gene when a T cell is near a cancer cell. CAR-T cells can recognize tumor antigens, triggering the switch, which in turn activates the added gene.

To test how it worked, the researchers connected one of these switches to a gene that produces a fluorescent protein. By observing the light emitted, they were able to track the switch turning on, off and on again.

In the future, instead of a fluorescent protein, the switch could be linked to the production of a therapeutic substance, allowing its release to be controlled in response to the cell's state. This approach will enable researchers to design cells that release therapeutic molecules only when they are needed, reducing the risk of side effects and increasing the effectiveness of therapies. The technology is ready for testing in collaboration with clinical immunologists.

Publication details

Giuliano Bonfá et al., A modular synthetic promoter toolkit for programmable gene control in activated and chronically stimulated T cells, Nature Communications (2026). DOI: 10.1038/s41467-026-77730-7

Journal information: Nature Communications

Who's behind this story?

Gaby Clark

Gaby Clark

MA in English, copy editor since 2021 with experience in higher education and health content. Dedicated to trustworthy science news. Full profile →

Robert Egan

Robert Egan

Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →

Citation: Reversible genetic switches could give cancer immunotherapy more precise control (2026, October 14) retrieved 14 October 2026 from https://medicalxpress.com/news/2026-10-reversible-genetic-cancer-immunotherapy-precise.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

来源:Medical Xpress · medicalxpress.com